BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.

Investor logo

Warning

This publication doesn't include Faculty of Medicine. It includes Faculty of Informatics. Official publication website can be found on muni.cz.

Authors

ŠIMARA Pavel PETERKOVÁ Martina STEJSKAL Stanislav POTĚŠILOVÁ Michaela KRONTORÁD KOUTNÁ Irena RÁČIL Zdeněk RÁZGA Filip JURČEK Tomáš DVOŘÁKOVÁ Dana MAYER Jiří

Year of publication 2012
Type Article in Periodical
Magazine / Source Leukemia & lymphoma
MU Faculty or unit

Faculty of Informatics

Citation
Web http://www.ncbi.nlm.nih.gov/pubmed/22233112
Doi http://dx.doi.org/10.3109/10428194.2012.656104
Field Oncology and hematology
Keywords p-CrkL; chronic myeloid leukemia; imatinib
Description In this study, we assessed BCR-ABL kinase activity by measuring the protein levels of CrkL and its phosphorylated form (p-CrkL) in order to predict the clinical outcome of newly diagnosed chronic myeloid leukemia patients. CD34+ cells from these patients were collected before the start of imatinib therapy and treated in vitro with imatinib. The reduction of p-CrkL and CrkL protein levels was then measured by flow cytometry. The data were processed using three independent approaches: an assessment of a) IC50imatinib, b) p-CrkL/CrkL ratio, and c) p-CrkL ratio. The results were subsequently correlated with the clinical response of patients after 3 and 6 months of imatinib therapy. None of the three p-CrkL parameters measured in CD34+ cells was found to be predictive of clinical outcome.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info